Arbutus Biopharma (ABUS) Patent Revocation Leads to 18% Stock Crash
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy ABUS?
Source: stocktwits
- Patent Revocation Impact: The European Patent Office revoked Arbutus's EP 2279254 patent on January 15, causing its stock to plummet over 18% on Friday, marking the largest intraday decline since July 2020, indicating market concerns about the company's future legal standing.
- Legal Response Plan: Arbutus plans to seek a review from the Enlarged Board of Appeal, asserting that the ruling will not affect its patent infringement cases against Moderna in the U.S., Canada, and Japan, demonstrating its confidence in ongoing legal battles.
- Market Reaction: Despite the sharp decline in stock price, retail sentiment on Stocktwits shifted from bearish to bullish, with some users viewing the drop as an opportunity to establish new positions, reflecting divergent views on the company's long-term prospects.
- Competitor Dynamics: While Arbutus's stock fell, Moderna's shares rose by 7%, and Merck's fell by 2%, highlighting varying market reactions to competitors that could influence Arbutus's competitive position moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABUS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABUS
Wall Street analysts forecast ABUS stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.720
Low
7.00
Averages
7.00
High
7.00
Current: 4.720
Low
7.00
Averages
7.00
High
7.00
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arbutus and Take-Two Options Trading Activity
- Arbutus Options Volume: Arbutus Biopharma Corp (ABUS) has seen an options volume of 10,247 contracts today, representing approximately 1 million underlying shares, which accounts for 47.7% of its average daily trading volume of 2.1 million shares over the past month, indicating heightened market interest in its future performance.
- High Volume Put Options: Within ABUS, the $4 strike put option has traded 2,782 contracts today, equating to about 278,200 shares, reflecting investor expectations of potential declines in the stock, which could influence its price volatility.
- Take-Two Options Volume: Take-Two Interactive Software, Inc. (TTWO) has recorded an options volume of 13,787 contracts today, representing approximately 1.4 million underlying shares, which is 44.9% of its average daily trading volume of 3.1 million shares over the past month, showcasing active trading interest in its stock.
- TTWO High Volume Put Options: The $185 strike put option for TTWO has seen a trading volume of 5,070 contracts today, representing about 507,000 shares, indicating a cautious sentiment among investors regarding the stock's future performance, which may impact its market behavior.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Midday Market Moves: Notable Stock Fluctuations
- CoreWeave Partnership: CoreWeave's stock surged 8% following a multiyear agreement with Perplexity, which will utilize CoreWeave's platform for next-generation inference workloads, enhancing its competitive edge in the cloud market.
- Broadcom Earnings Anticipation: Broadcom shares rose 2% as investors await its fiscal first-quarter earnings report, with analysts projecting earnings of $2.03 per share and revenue of $19.18 billion, indicating strong market confidence in its performance.
- Dow Inc Upgrade Impact: Dow Inc's stock increased by 4% after KeyBanc upgraded its rating from sector weight to overweight, citing that rising oil prices will benefit U.S. ethylene producers, reflecting optimistic market expectations for its profitability.
- Moderna Lawsuit Settlement: Moderna's shares climbed 12% after the company agreed to pay up to $2.25 billion to settle a lawsuit with Arbutus Biopharma and Genevant Sciences over a Covid vaccine patent, demonstrating proactive legal risk management.
See More
Moderna Settles Patent Dispute with Arbutus and Genevant
- Patent Settlement Agreement: Moderna has agreed to pay $950 million to settle a patent dispute with Arbutus Biopharma and Genevant Sciences, removing a significant legal overhang that is expected to boost market confidence in the company.
- Potential Additional Liability: Under the agreement, Moderna may face up to an additional $1.3 billion payment within 90 days depending on the Federal Circuit's ruling, introducing a layer of uncertainty that could impact its future financial performance.
- Positive Analyst Sentiment: Citi analysts believe the deal alleviates negative pressure on the stock, noting that while it is not the best-case scenario, it is better than feared, with William Blair analysts also viewing it as a positive clearing event.
- Reduced Litigation Costs: J.P. Morgan analysts highlight that the maximum $2.3 billion Moderna must pay is significantly lower than the previously estimated $5 billion, demonstrating effective cost control in the settlement that may contribute to the company's future financial stability.
See More
STAAR Surgical Reports Disappointing Q4 Results, Shares Plummet
- Disappointing Earnings: STAAR Surgical reported a fourth-quarter loss of $0.13 per share, significantly missing the analyst consensus estimate of a $0.06 profit, indicating major challenges in profitability.
- Sales Decline: The company's quarterly sales totaled $57.801 million, falling short of the analyst consensus estimate of $75.370 million, reflecting weak market demand and increased competitive pressure.
- Stock Reaction: In pre-market trading, STAAR Surgical's shares dropped 10.2% to $16.99, indicating investor concerns about the company's future prospects following the disappointing earnings report.
- Market Impact: This earnings report not only affects STAAR Surgical's stock price but may also negatively impact its market position in the medical device industry, prompting investors to monitor potential strategic adjustments going forward.
See More
Moderna Settles for $950 Million with Arbutus, Eyes Future Growth
- Settlement Agreement: Moderna has reached a $950 million settlement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine Spikevax and mRESVIA product, which is expected to be paid in the third quarter, significantly alleviating the company's legal burdens.
- Potential Additional Payments: Depending on the outcome of a legal appeal regarding government-contractor immunity, Moderna may face up to $1.3 billion in additional payments, which would represent the largest disclosed patent settlement in the pharmaceutical industry, further impacting the company's financial outlook.
- Future Growth Outlook: CEO Stéphane Bancel emphasized that resolving this legacy issue allows the company to focus on the future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and equivalents, aiming to return to revenue growth in 2026 and achieve breakeven by 2028.
- Positive Market Reaction: The settlement amount was better than feared, leading to an 8.85% increase in Moderna's stock price during Wednesday's premarket trading, currently at $54.24, close to its 52-week high, reflecting investor confidence in the company's future prospects.
See More
Arbutus and Take-Two Options Trading Activity
- Arbutus Options Volume: Arbutus Biopharma Corp (ABUS) has seen an options volume of 10,247 contracts today, representing approximately 1 million underlying shares, which accounts for 47.7% of its average daily trading volume of 2.1 million shares over the past month, indicating heightened market interest in its future performance.
- High Volume Put Options: Within ABUS, the $4 strike put option has traded 2,782 contracts today, equating to about 278,200 shares, reflecting investor expectations of potential declines in the stock, which could influence its price volatility.
- Take-Two Options Volume: Take-Two Interactive Software, Inc. (TTWO) has recorded an options volume of 13,787 contracts today, representing approximately 1.4 million underlying shares, which is 44.9% of its average daily trading volume of 3.1 million shares over the past month, showcasing active trading interest in its stock.
- TTWO High Volume Put Options: The $185 strike put option for TTWO has seen a trading volume of 5,070 contracts today, representing about 507,000 shares, indicating a cautious sentiment among investors regarding the stock's future performance, which may impact its market behavior.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Midday Market Moves: Notable Stock Fluctuations
- CoreWeave Partnership: CoreWeave's stock surged 8% following a multiyear agreement with Perplexity, which will utilize CoreWeave's platform for next-generation inference workloads, enhancing its competitive edge in the cloud market.
- Broadcom Earnings Anticipation: Broadcom shares rose 2% as investors await its fiscal first-quarter earnings report, with analysts projecting earnings of $2.03 per share and revenue of $19.18 billion, indicating strong market confidence in its performance.
- Dow Inc Upgrade Impact: Dow Inc's stock increased by 4% after KeyBanc upgraded its rating from sector weight to overweight, citing that rising oil prices will benefit U.S. ethylene producers, reflecting optimistic market expectations for its profitability.
- Moderna Lawsuit Settlement: Moderna's shares climbed 12% after the company agreed to pay up to $2.25 billion to settle a lawsuit with Arbutus Biopharma and Genevant Sciences over a Covid vaccine patent, demonstrating proactive legal risk management.
See More
Moderna Settles Patent Dispute with Arbutus and Genevant
- Patent Settlement Agreement: Moderna has agreed to pay $950 million to settle a patent dispute with Arbutus Biopharma and Genevant Sciences, removing a significant legal overhang that is expected to boost market confidence in the company.
- Potential Additional Liability: Under the agreement, Moderna may face up to an additional $1.3 billion payment within 90 days depending on the Federal Circuit's ruling, introducing a layer of uncertainty that could impact its future financial performance.
- Positive Analyst Sentiment: Citi analysts believe the deal alleviates negative pressure on the stock, noting that while it is not the best-case scenario, it is better than feared, with William Blair analysts also viewing it as a positive clearing event.
- Reduced Litigation Costs: J.P. Morgan analysts highlight that the maximum $2.3 billion Moderna must pay is significantly lower than the previously estimated $5 billion, demonstrating effective cost control in the settlement that may contribute to the company's future financial stability.
See More
STAAR Surgical Reports Disappointing Q4 Results, Shares Plummet
- Disappointing Earnings: STAAR Surgical reported a fourth-quarter loss of $0.13 per share, significantly missing the analyst consensus estimate of a $0.06 profit, indicating major challenges in profitability.
- Sales Decline: The company's quarterly sales totaled $57.801 million, falling short of the analyst consensus estimate of $75.370 million, reflecting weak market demand and increased competitive pressure.
- Stock Reaction: In pre-market trading, STAAR Surgical's shares dropped 10.2% to $16.99, indicating investor concerns about the company's future prospects following the disappointing earnings report.
- Market Impact: This earnings report not only affects STAAR Surgical's stock price but may also negatively impact its market position in the medical device industry, prompting investors to monitor potential strategic adjustments going forward.
See More
Moderna Settles for $950 Million with Arbutus, Eyes Future Growth
- Settlement Agreement: Moderna has reached a $950 million settlement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine Spikevax and mRESVIA product, which is expected to be paid in the third quarter, significantly alleviating the company's legal burdens.
- Potential Additional Payments: Depending on the outcome of a legal appeal regarding government-contractor immunity, Moderna may face up to $1.3 billion in additional payments, which would represent the largest disclosed patent settlement in the pharmaceutical industry, further impacting the company's financial outlook.
- Future Growth Outlook: CEO Stéphane Bancel emphasized that resolving this legacy issue allows the company to focus on the future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and equivalents, aiming to return to revenue growth in 2026 and achieve breakeven by 2028.
- Positive Market Reaction: The settlement amount was better than feared, leading to an 8.85% increase in Moderna's stock price during Wednesday's premarket trading, currently at $54.24, close to its 52-week high, reflecting investor confidence in the company's future prospects.
See More
